5d 1m 3m 1y 5y 10y
There are no Transcripts on AXN.
Aoxing Pharmaceutical Company, Inc. Announces Financial Results for Second Quarter of 2014 Fiscal YearMarketwire (Feb 19, 2014)
Marketwire (Jan 15, 2014)
AXN vs. ETF Alternatives
Wednesday, Feb 193:43 PM
Tuesday, Oct 162012, 3:36 PMAoxing Pharmaceutical (AXN +7.4%) pops after the drug-maker reported a $15.9M net loss for FY12, but total revenue rose 22% year over year to $8.13M. The revenue gain was largely due to a 33% increase in sales of the company's main product, Zhongtongan, which is now being marketed for gynecological and orthopedic applications, in addition to its core dental market. Overall, Zhongtongan accounted for 89% of the company's FY12 sales. |Tuesday, Oct 162012, 3:36 PM| Comment!
Thursday, Sep 132012, 3:31 PM